TB-500 (Thymosin Beta-4) · Research brief

Difference Between BPC-157 and TB-500: Research Guide

Real Peptides Research TeamEditorial

Updated April 3, 20269 min read

50 WORDS

Short answer

Most side-by-side comparisons of these two peptides get the second one wrong before the first paragraph ends. TB-500 is routinely described as thymosin beta-4, but material supplied under that code is typically a short synthetic fragment based on the actin-binding region of the parent protein, not the full 43-residue protein.

Key takeaways

BPC-157 is a 15-amino-acid synthetic peptide of roughly 1,419 Da, while TB-500 is a much smaller acetylated seven-residue fragment of around 0.9 kDa.
TB-500 and thymosin beta-4 are not the same molecule: the parent protein contains 43 amino acids and weighs roughly 4.9 kDa.
The mechanistic difference between BPC-157 and TB-500 is signaling versus structure, with BPC-157 studied through VEGFR2 and nitric oxide pathways and thymosin beta-4 studied as a G-actin sequestering protein.
Most peer-reviewed thymosin beta-4 data describes the full-length protein, so applying it to the seven-mer fragment is an inference that should be controlled for.
BPC-157 appears on the WADA Prohibited List under section S0 as of 2022, and on the FDA Category 2 bulk drug substances list.
CAS number and molecular weight on a batch certificate of analysis are the only reliable way to confirm which molecule a vial actually contains.

Our team fields this question constantly from labs sourcing both compounds for the same tissue-repair model. The researchers who end up with reproducible data are the ones who read the certificate of analysis for molecular weight and CAS number first, and compare price second.

What is the difference between BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid peptide based on a sequence from human gastric juice protein, with a molecular weight near 1,419 Da. TB-500 is a far smaller synthetic fragment, roughly 0.9 kDa, derived from the actin-binding motif of thymosin beta-4. They differ in origin, size, and reported mechanism.

The oversimplification worth killing off is that both are interchangeable repair peptides doing the same job by the same route. They aren't. One is studied as a signaling peptide acting on angiogenic pathways, the other as a structural peptide that binds monomeric actin directly. What follows covers molecular identity and how to verify it, the two mechanisms as the published literature describes them, and the criteria research teams actually use when choosing between the two compounds.

Two molecules, two completely different origins

The difference between BPC-157 and TB-500 starts with the source material, not the effect. BPC-157, short for Body Protection Compound 157, is a synthetic pentadecapeptide: 15 amino acids, sequence GEPPPGKPADDAGLV, based on a partial sequence of a protein isolated from human gastric juice. Its CAS number is commonly listed as 137525-51-0, with a molecular weight near 1,419 Da. It is a designed fragment, not a circulating hormone.

TB-500 is a different animal. Thymosin beta-4 is a naturally occurring 43-amino-acid protein of roughly 4.9 kDa, present in most mammalian cells and abundant in platelets and wound fluid. TB-500, as the code is used across research supply, almost always refers to the acetylated seven-residue actin-binding motif LKKTETQ, commonly listed under CAS 885340-08-9. Full-length thymosin beta-4 carries its own identifier, commonly listed as CAS 77591-33-4.

Why this matters practically: a vial labeled TB-500 and a vial labeled thymosin beta-4 can contain molecules separated by around 36 amino acids. In our experience reviewing procurement enquiries, this is the most frequent single point of confusion in the entire category. Two vials, two prices, one assumption, and a study design resting on literature that may not describe the molecule sitting in the freezer.

Signaling cascades versus direct structural binding

Mechanistically, the difference between BPC-157 and TB-500 is roughly the difference between talking to a cell and rearranging its scaffolding.

Research on BPC-157, a large share of it originating from groups associated with the University of Zagreb, describes activity through the nitric oxide system and angiogenic signaling. Studies report upregulation of VEGFR2 (vascular endothelial growth factor receptor 2), downstream Akt and eNOS activity, and involvement of the FAK-paxillin pathway that governs how fibroblasts adhere and migrate. Tendon fibroblast work in the literature also reports increased growth hormone receptor expression. The reported action is indirect: signal, cascade, cellular response.

Thymosin beta-4 operates by physical contact. It is described as the principal G-actin sequestering protein in mammalian cells, binding monomeric actin and maintaining the unpolymerized pool cells draw on when they migrate. No definitive receptor has been characterized for it, which is unusual for a molecule with that breadth of reported activity. The LKKTETQ motif carried by TB-500 is the segment implicated in that actin interaction.

Here's the caveat nearly every comparison skips. Almost all of the peer-reviewed data sits on full-length thymosin beta-4, not on the seven-residue fragment. Assuming the fragment reproduces the parent protein's reported behaviour is an inference, not a finding, and control arms should be designed as if that assumption might fail.

What actually drives compound selection in a study design

Selection usually comes down to four variables: route, stability, maturity of the evidence base, and regulatory status.

Route first. BPC-157 is repeatedly described in the literature as stable in human gastric juice, which is why oral-administration rodent models appear throughout its published record. Short thymosin beta-4 fragments are not characterized that way, and TB-500 work is overwhelmingly parenteral in animal models.

Stability and handling are similar on paper and different in practice. Both arrive as lyophilised white powder, both are water-soluble, and both follow standard peptide cold-chain documentation: long-term storage of the lyophilised vial at minus 20 degrees Celsius, refrigeration at 2 to 8 degrees Celsius for reconstituted solution over short working windows. Repeated freeze-thaw cycling degrades either compound, and no visual inspection detects it.

Evidence maturity diverges sharply. Thymosin beta-4 has progressed into human clinical investigation, notably in ophthalmology, while the BPC-157 record remains overwhelmingly preclinical and rodent-based. Neither compound holds FDA approval for any indication, BPC-157 has been placed on the FDA's Category 2 list of bulk drug substances raising significant safety concerns for compounding, and the World Anti-Doping Agency added BPC-157 to its Prohibited List in 2022 under section S0, with thymosin beta-4 peptides prohibited under the growth factor category. Everything here is educational, describes laboratory research material only, and applies to no human or veterinary use. Real Peptides supplies both compounds strictly for laboratory research, with small-batch synthesis and publicly posted batch documentation.

Difference Between BPC-157 and TB-500: Attribute Comparison

This table compresses the sourcing decision into the variables that actually change a protocol. Everything below describes reported research characteristics of research-use-only material.

Attribute	BPC-157	TB-500	Bottom Line for Researchers
Molecular identity	Synthetic 15-amino-acid pentadecapeptide, sequence GEPPPGKPADDAGLV, CAS commonly listed as 137525-51-0	Acetylated seven-residue actin-binding motif LKKTETQ, CAS commonly listed as 885340-08-9	Verify against CAS and molecular weight on the COA before ordering, because product codes are inconsistent across suppliers
Size	Approximately 1,419 Da	Approximately 0.9 kDa, versus roughly 4.9 kDa for full-length thymosin beta-4	If your literature review cites thymosin beta-4, you may be citing a molecule five times larger than the vial you bought
Parent molecule	Partial sequence of a protein found in human gastric juice; no circulating full-length analogue	Fragment of thymosin beta-4, an endogenous protein abundant in platelets and wound fluid	Only TB-500 has a naturally occurring parent protein with its own independent literature
Reported mechanism	Angiogenic and nitric oxide signaling, VEGFR2, Akt and eNOS, FAK-paxillin pathway activity	Direct G-actin sequestration supporting cytoskeletal remodelling and cell migration	Receptor-adjacent signaling versus structural binding: the two are not redundant in a shared model
Evidence base	Extensive preclinical rodent literature, heavily concentrated in a small number of research groups	Parent protein has reached human clinical investigation; the fragment itself has far thinner direct data	Neither has a mature independent human evidence base for the exact molecule sold under the code
Handling	Lyophilised powder, water-soluble, minus 20 degrees Celsius long-term storage	Lyophilised powder, water-soluble, same cold-chain expectations	Storage discipline matters more than compound choice; degradation is invisible without assay
Regulatory and anti-doping status	No FDA approval; placed on the FDA Category 2 bulk substances list; WADA Prohibited List since 2022 under S0	No FDA approval; thymosin beta-4 peptides prohibited under WADA growth factor provisions	Both are research use only and neither is a therapeutic product under any regulatory framework

What If: Sourcing and Study Design Scenarios

What if the certificate of analysis lists a molecular weight I don't recognise?

Stop and reconcile the mass against the expected sequence before the material enters a protocol. A TB-500 vial reporting a mass near 4.9 kDa contains full-length thymosin beta-4, not the seven-residue fragment, and a BPC-157 vial should land close to 1,419 Da. Mass spectrometry and HPLC purity data on a batch-specific certificate exist precisely so this check takes thirty seconds. A mismatch is not a rounding issue, it is a different compound.

What if my literature review is built on thymosin beta-4 papers?

Cite them as thymosin beta-4 papers and state explicitly that the test article is a fragment. The seven-residue actin-binding motif carries the region implicated in actin interaction, but the parent protein has additional domains and a substantially longer sequence. Research teams that blur the two in a methods section make their own results harder to replicate and harder to publish. Naming the exact molecule is a small discipline with large downstream value.

What if a protocol calls for both compounds in the same model?

Build separate single-compound arms before any combined arm, because the reported mechanisms are independent rather than overlapping. Angiogenic signaling and cytoskeletal actin dynamics produce different readouts, and a combined arm without isolated controls cannot attribute an effect to either compound. Our team has seen more study designs fail on missing control arms than on compound purity.

What if two suppliers quote very different prices for the same code?

Compare the documentation, not the label. Price gaps in this category usually reflect purity thresholds, batch size, synthesis scale, and whether third-party analytical testing is published rather than merely claimed. A vial without a batch-matched certificate of analysis is an unknown quantity at any price, and unknown quantities cost more in wasted experiment time than they ever save on invoice.

The Unflattering Truth About Comparing These Two Peptides

Let's be direct about this: most of the confident comparisons circulating online are comparing a well-characterized 43-amino-acid protein against a 15-amino-acid synthetic fragment, then attaching the conclusion to a seven-residue peptide that neither body of research studied. The difference between BPC-157 and TB-500 is real and mechanistically clear. What is not clear is how much thymosin beta-4 literature legitimately transfers to TB-500 material. Anyone claiming certainty there is overreaching, and research designs should treat that gap as an open question rather than a settled one.

Researchers comparing the two directly can review the BPC-157 and TB-500 listings with batch-specific documentation, alongside the BPC-157 capsule format requested for oral-route animal models. Deeper background sits on the BPC-157 research page, the TB-500 research page, and the BPC-157 questions page. Every batch certificate of analysis is published, the full catalog lists compounds by sequence and CAS number, and shipping coverage is listed separately.

The difference between BPC-157 and TB-500 is not really a contest between two repair compounds, it is a lesson in how casually peptide nomenclature travels ahead of peptide chemistry. One code names a specific 15-amino-acid sequence that has never existed as anything but a designed fragment. The other names a seven-residue motif that borrowed its reputation from a much larger protein. Knowing which molecule is actually in the vial, confirmed by CAS number and mass, is the part of this comparison that changes results.

References

Peer-reviewed sources on BPC-157 indexed in PubMed, listed for research context. Real Peptides supplies BPC-157 for laboratory research use only.

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949. doi:10.1177/15563316251355551
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999. doi:10.3390/ph18020185
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine, 2025. PMID 40789979. doi:10.1007/s12178-025-09990-7
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel, Switzerland), 2024. PMID 39204186. doi:10.3390/ph17081081
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences, 2026. PMID 41898733. doi:10.3390/ijms27062876
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International journal of molecular sciences, 2026. PMID 42278509. doi:10.3390/ijms27114984
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Scientific reports, 2026. PMID 42204242. doi:10.1038/s41598-026-55449-1
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026. PMID 42542926. doi:10.52312/jdrs.2026.2951

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

BPC-157 is a synthetic 15-amino-acid peptide of roughly 1,419 Da based on a sequence from human gastric juice protein. TB-500 is a much smaller acetylated seven-residue fragment, around 0.9 kDa, based on the actin-binding motif LKKTETQ found in thymosin beta-4. The published literature describes BPC-157 acting through angiogenic and nitric oxide signaling pathways, while thymosin beta-4 is described as a G-actin sequestering protein acting on cytoskeletal dynamics. Both are research-use-only compounds and neither holds FDA approval for any indication.

No. Thymosin beta-4 is a naturally occurring 43-amino-acid protein of roughly 4.9 kDa, while material supplied as TB-500 is usually the acetylated seven-residue actin-binding motif LKKTETQ. They carry different CAS numbers, commonly listed as 77591-33-4 for the full protein and 885340-08-9 for the fragment. Because most peer-reviewed research describes the full-length protein, applying that literature to the fragment is an inference rather than a documented finding.

BPC-157 research describes indirect signaling activity, including upregulation of VEGFR2, downstream Akt and eNOS involvement in the nitric oxide system, and effects on the FAK-paxillin pathway governing fibroblast adhesion and migration. Thymosin beta-4 research describes a direct structural action, binding monomeric G-actin and maintaining the unpolymerized pool cells use for migration. One is a signaling story, the other is a cytoskeletal one, which is why the two are not considered redundant in a shared research model.

Both compounds are supplied as research chemicals for laboratory use by qualified researchers and institutions, not as drugs or supplements for human or veterinary consumption. Real Peptides supplies both for laboratory research only, with batch-specific certificates of analysis available for verification. Purchasers are responsible for confirming compliance with the regulations that apply to their own institution and jurisdiction.

Pricing varies widely by vial quantity, synthesis scale, purity threshold, and whether third-party analytical testing is published. Large price gaps between suppliers for identical product codes usually reflect documentation quality rather than the molecule itself. The more useful comparison is whether each quote comes with a batch-matched certificate of analysis showing HPLC purity and mass confirmation, because material without that documentation is an unknown at any price.

BPC-157 is commonly listed under CAS 137525-51-0 with a molecular weight near 1,419 Da. TB-500 as the seven-residue fragment is commonly listed under CAS 885340-08-9 at roughly 0.9 kDa, while full-length thymosin beta-4 is commonly listed under CAS 77591-33-4 at approximately 4.9 kDa. If the reported mass on a certificate does not match the CAS number printed beside it, the vial contains something other than what the label claims.

Yes. The World Anti-Doping Agency added BPC-157 to its Prohibited List in 2022 under section S0, which covers substances with no current approval by any governmental regulatory health authority for human therapeutic use. Thymosin beta-4 peptides fall under WADA's prohibited growth factor provisions. Athletes subject to anti-doping testing should treat both as prohibited at all times.

Standard peptide documentation calls for long-term storage of the lyophilised powder at minus 20 degrees Celsius, protected from light and moisture. Once in solution, refrigeration at 2 to 8 degrees Celsius over short working windows is the usual handling standard. Repeated freeze-thaw cycling degrades peptide integrity, and that degradation is not detectable by visual inspection, which is why aliquoting is standard practice in most labs.

BPC-157 is repeatedly described in the published literature as stable in human gastric juice, which is why oral-administration rodent models appear throughout its research record. Short thymosin beta-4 fragments have not been characterized with comparable gastric stability, so TB-500 work in animal models is overwhelmingly parenteral. That stability profile, not potency, is the main reason a capsule format exists for one compound and not the other.

Thymosin beta-4 has the deeper record, including progression into human clinical investigation, notably in ophthalmology. BPC-157 has an extensive preclinical literature that is heavily concentrated among a small number of research groups and remains almost entirely animal-based. The important qualifier is that the strongest thymosin beta-4 data describes the full 43-amino-acid protein rather than the seven-residue fragment supplied as TB-500.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA